7 Hills Pharma Safely Doses First Patient in Phase 1b/2a Clinical Trial Testing Alintegimod Against aPD-1-resistant Solid Tumors

September 03, 2024 14:02 ET | Source: 7 Hills Pharma HOUSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- 7 Hills Pharma Inc. (“7 Hills” or “7HP”), a clinical-stage pharma company advancing first-in-class integrin activators designed to safely enhance cancer immunotherapies, announced today that their first cancer patient has been safely dosed with alintegimod, an integrin-targeted agonist that may augment T cell activation and trafficking in patients who are resistant to immune checkpoint inhibitors. "Treating a courageous first cancer patient is a significant step forward in our mission to deliver safer, more effective, and more accessible immunotherapy" This multicenter Phase 1b/2a study ( NCT06362369 ) is supported by a $13.4 million award from the Cancer Prevention and Research Institute of Texas (DP230062) and a $2.0 million award from the National Cancer Institute (R44CA285207). Alintegimod leverages a novel mechanism of action, pioneered by the co-founders of 7 Hills Pharma, to enhance rate-limiting steps in the cancer immunity cycle required for immune cell trafficking, antigen presentation and T cell activation. “We are full of gratitude as we reach this important milestone in the clinical development of alintegimod,” said Lionel D. Lewis, Chief Medical Officer of 7 Hills Pharma. “Treating a courageous first cancer patient is a significant step forward in our mission to deliver safer, more effective, and more accessible immunotherapy options for many patients with hard-to-treat cancers.” About 7 Hills Pharma Inc. 7 Hills Pharma is a clinical-stage immunotherapy company developing a platform of novel small molecules for the treatment of cancer and augmentation of stem cell therapies. Our compounds are first-in-concept allosteric integrin activators that leverage a unique mechanism of action to stabilize the cell-cell interactions required to effectively mount an immune response and to more quickly engraft transplanted hematopoietic stem cells. For more information, visit http://www.7hillspharma.com . About Alintegimod Alintegimod is 7 Hills Pharma’s lead, clinical-stage integrin activator. It is a first-in-class, orally delivered small molecule that is designed to safely augment antigen-specific immune responses by selectively activating the integrins LFA-1 and VLA-4. In preclinical models, alintegimod has been shown to improve the effectiveness of a broad range of immune checkpoint inhibitors. In a Phase I clinical trial, alintegimod demonstrated oral bioavailability and a clean safety profile at exposures well exceeding therapeutic levels. See the original article here | Global Newswire Clinical Trials Cancer Anti-PD-1-resistant Immunotherapy integrin agonists T cell activation Rob Bent Next Next 7 Hills Pharma Receives $4.7MM Gra​nt to Advance First-in-class Cell/Gene Therapy Technology into the Clinic 2450 Holcombe Blvd, Suite J Houston, TX 77021 [email protected] © 2025. 7 Hills Pharma Inc. Menu Home About Leadership Technology News & Publications Contact Newsletter Block This newsletter signup form needs a storage option. Edit the block and enter a storage location via the Storage tab. Subscribe Sign up with your email address to receive news and updates. Email Address Sign Up We respect your privacy. Thank you!

The release as fetched from its publisher. 7hillspharma.com ↗